Business Context and Reporting Period
This Form 8-K Current Report was filed by Capricor Therapeutics, Inc. on April 8, 2025. The filing addresses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements.
Material Changes
Board Departure: Mr. Earl Collier, a member of the Board of Directors, informed the Board on April 8, 2025, that he will not stand for re-election at the Annual Meeting of Shareholders scheduled for May 22, 2025.
- Reason for Departure: The resignation is not due to any disagreement with the Company regarding operations, policies, or practices.
- Future Engagement: The Company plans to enter into a consulting agreement with Mr. Collier to perform strategic advisory relations from time to time.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on business outlook, or new risk factors. The only contingency noted is the transition of Mr. Collier from a director to a strategic advisor.
Investor Verification Checklist
- Confirm the exact date of the Annual Meeting of Shareholders (stated as May 22, 2025).
- Verify the terms of the proposed consulting agreement with Mr. Collier, including compensation details, which are not specified in this filing.
- Monitor subsequent filings for the appointment of a new director to fill the vacancy left by Mr. Collier.